Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies

Executive Summary

The pharmaceutical industry's manufacturing capacity for cell and gene therapies is under pressure from an ever-increasing number of life sciences companies wanting to exploit rare expertise in the sector, but CMOs and government-backed facilities are rapidly coming on-stream, hoping to develop local clusters of companies to deliver the complete "living medicines" supply chain.

Advertisement

Related Content

Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says
How Merck KgaA’s Life Science Unit Is Riding The Crest Of The Gene Therapy Wave
Lilly, Novartis, Jazz and Ionis Take New Products To EMA
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Curative Regenerative Medicines: Preparing Health Care Systems For The Coming Wave

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel